Hypertension and targeted therapy
Authors:
- 15 June 2006
- journal article
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (3) , 172-178
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Mechanisms of Hypertension Associated With BAY 43-9006Journal of Clinical Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summaryBMJ, 2004
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584Seminars in Oncology, 2003